Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Hypercalcaemia at Diagnosis Is an Independent Predictor of Poor Survival in Diffuse Large B-Cell Lymphoma

Michael P Gilbertson, MBBS,FRACP,FRCPA, Maciej Tatarczuch, BMBS, FRACP, FRCPA, Ashish Kumar Panigrahi, MBBS, Samuel Robinson, David Wong, PhD, Pasquale L. Fedele, FRACP, FRCPA, Gareth Gregory, MBBS,PhDFRACP,FRCPA, George Grigoriadis, MBBS PhDFRACP FRCPA, Michael S. Low, MBBS, Sushrut S. Patil, FRACP, FRCPA, Sumita Ratnasingham, FRACP, FRCPA, Jake Shortt, MBBS PhDFRACP FRCPA, Fathima Shahla Vilcassim, MBBS, FRACP, FRCPA, Jonathan Wong, MBBS, Sophie Lee, FRACP, FRCPA, PhD, Duncan P. Carradice, MBBS, FRCPA, FRACP, William E. P. Renwick, MBBS, FRACP, FRCPA, Stephen Opat, FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 1568.

https://doi.org/10.1182/blood.V130.Suppl_1.1568.1568

Published: 2017

Journal Articles

BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma

Constantine S. Tam, MD, Hang Quach, MBBS, MD, Andrew Nicol, Xavier Badoux, Hannah Rose, H. Miles Prince, MD FRACP, FRCPA, Michael F. Leahy, FRACP,FRCPath,FRCP, Richard Eek, MBCHB, Nicholas Wickham, FRCPA,FRACP,FRCPath, Sushrut S. Patil, FRACP, FRCPA, Jane Huang, MD, Xiaoping Zhang, MD PhD, Lai Wang, PhD, Eric Hedrick, MD, William Novotny, Ian W. Flinn, MD PhD

Blood (2017) 130 (Supplement 1): 1745.

https://doi.org/10.1182/blood.V130.Suppl_1.1745.1745

Published: 2017

Journal Articles

Post-Allogeneic Stem Cell Transplant Surveillance of CD34+ Sorted Peripheral Blood to Quantify Emergent DNMT3A, IDH and NPM1 clones and Correlation with Clinical Outcome

Shaun Fleming, MBBS(Hons) FRACP FRCPA, Nik Cummings, Tongted Das, Adam Ivey, BSc, MSc, PhD, Julie McManus, Sharon Avery, MBBS, FRACP, FRCPA, Sushrut S. Patil, FRACP, FRCPA, Patricia A. Walker, MBBS, David J. Curtis, MBBS,PhD FRACP, FRCPA, Andrew Spencer, MD, Andrew Wei, MBBS, PhD FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 2674.

https://doi.org/10.1182/blood.V130.Suppl_1.2674.2674

Published: 2017

Journal Articles

Improved Survival of Older Patients with Mantle Cell Lymphoma (MCL) with Front-Line Cytarabine-Based Immunochemotherapy

Sumita Ratnasingam, MBBS, Michael Gilbertson, Zoe McQuilten, MBBS, Kay T Htun, George Grigoriadis, MBBS, PhD BSc, Swe Myo Htet, MBBS, Philip Campbell, MBBS, FRACP, FRCPA, Khai Li Chai, MBBS, Hang Quach, MBBS (Hons), FRACP, FRCPA, MD, Sushrut S. Patil, FRACP, FRCPA, Jake Shortt, MD, Stephen Opat, MD

Blood (2016) 128 (22): 2965.

https://doi.org/10.1182/blood.V128.22.2965.2965

Published: 2016

Journal Articles

Autologous Stem Cell Transplantation (ASCT) Followed By Outpatient-Based Non-Myeloblative Allogeneic (NMA) Stem Cell Transplantation (Tandem Auto-Allo) for Biologically Adverse Multiple Myeloma (MM). a Single Centre Experience from Australia

Anish Puliyayil Nair, MD DM, Patricia A. Walker, MBBS, FRACP, FRCPA, Anna Kalff, MBBS, FRACP, FRCPA, Krystal Bergin, MBBS, Sharon Avery, MBBS (Hons), FRACP, FRCPA, David J. Curtis, MD, PhD, Sushrut S. Patil, FRACP, FRCPA, Jenny Muirhead, Tongted Phomoonna, Daniela Klarica, RN, Andrew Spencer

Blood (2015) 126 (23): 2030.

https://doi.org/10.1182/blood.V126.23.2030.2030

Published: 2015

Journal Articles

Comparison of Cyclophosphamide/Total Body Irradiation (Cy/TBI) and Etoposide/Total Body Irradiation (Etop/TBI) Conditioned Allogeneic Stem Cell Transplant (alloHSCT) for Adult Acute Lymphoblastic Leukaemia (ALL), Data from an Australian Tertiary Care Centre

Anish Puliyayil Nair, MD DM, Shaun Fleming, MBBS (Hons), FRACP, FRCPA, Sharon Avery, MBBS (Hons), FRACP, FRCPA, David J. Curtis, MD, PhD, Sushrut S. Patil, FRACP, FRCPA, Patricia A. Walker, MBBS, FRACP, FRCPA, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Jenny Muirhead, Andrew Spencer

Blood (2015) 126 (23): 5543.

https://doi.org/10.1182/blood.V126.23.5543.5543

Published: 2015

Journal Articles

The Effect of Granulocyte-Colony-Stimulating Factor (G-CSF) on T Cell Polarization in Vitro : A Direct Comparison Between Nivestim® and Neupogen®

Nicole Mifsud, Amina Ismail, Elisha de Valle, Andrew Spencer, MD, Sushrut S. Patil, FRACP FRCPA, George Grigoriadis, MBBS, PhD BSc, Raffi Gugasyan

Blood (2014) 124 (21): 5803.

https://doi.org/10.1182/blood.V124.21.5803.5803

Published: 2014

Journal Articles

Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma Is Feasible, Efficacious and Associated With Low Transplant-Related Morbidity and Mortality

Philip Campbell, MBBS, FRACP, FRCPA, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, David J. Curtis, M.D., Ph.D., Anthony P. Schwarer, MD, Andrew H Wei, MBBS, PhD, Anna Kalff, MBBS, FRACP, FRCPA, Jenny Muirhead, Andrew Spencer, MD

Blood (2013) 122 (21): 2128.

https://doi.org/10.1182/blood.V122.21.2128.2128

Published: 2013

Journal Articles

Incidence and Kinetics Of Full Donor Chimerism and The Impact Of Minimal Residual Disease Status Following Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma

Philip Campbell, MBBS, FRACP, FRCPA, Tongted Das, David Kipp, Patricia A. Walker, MBBS, FRACP, FRCPA, Jenny Muirhead, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, David J. Curtis, M.D., Ph.D., Anthony P. Schwarer, MD, Anna Kalff, MBBS, FRACP, FRCPA, Andrew Spencer, MD

Blood (2013) 122 (21): 2129.

https://doi.org/10.1182/blood.V122.21.2129.2129

Published: 2013

Journal Articles

Azacitidine in Combination with the mTOR Inhibitor Everolimus in Relapsed and Refractory AML

Andrew H Wei, MBBS, PhD, Peter T. Tan, MBBS, John Catalano, MD, Patricia A. Walker, MBBS, FRACP, FRCPA, Anthony P. Schwarer, MD, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Stephen Opat, MD, Nik Cummings, BSc, Andrew Spencer, MD

Blood (2011) 118 (21): 2599.

https://doi.org/10.1182/blood.V118.21.2599.2599

Published: 2011

Journal Articles

Initial Remission Duration Is the Most Important Predictor of Outcome Following FLAG-Amsacrine Salvage of AML in First Relapse,

Chun Yew Fong, MBBS, George Grigoriadis, MBBS, PhD, BSc, Jay Hocking, MBBS, Philip Campbell, MBBS, FRACP, FRCPA, Anthony P. Schwarer, MD, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Hatem H. Salem, MD, FRACP, FRCPA, Andrew Spencer, MD, Andrew H Wei, MBBS, PhD

Blood (2011) 118 (21): 3631.

https://doi.org/10.1182/blood.V118.21.3631.3631

Published: 2011

Journal Articles

A Phase 1b Dose Escalation Safety Analysis of Lenalidomide and Azacitidine Maintenance Therapy for Poor Risk AML,

Andrew H Wei, MBBS, PhD, Peter T. Tan, MBBS, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Anthony P. Schwarer, MD, Elchanan H. Januszewicz, MBBS, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Wai Khoon Ho, MBBS FRACP FRCPA, Constantine S. Tam, MBBS, FRACP, FRCPA, Andrew Spencer, MD

Blood (2011) 118 (21): 3625.

https://doi.org/10.1182/blood.V118.21.3625.3625

Published: 2011

Journal Articles

A Retrospective Analysis of 344 Fludarabine Melphalan RIC Allogeneic Stem Cell Transplants for Myeloid and Lymphoid Malignancies In Australia and New Zealand 1998–2008,

Adam J Bryant, Elango Pillai, Glen Kennedy, Anna Kalff, David Ritchie, Biju George, Mark Hertzberg, Sushrut S. Patil, FRACP FRCPA, Andrew Spencer, MD, Keith Fay, Paul Cannell, Leanne Berkahn, Richard Doocey, Ruth Spearling, Ian Nivison-Smith, John Moore

Blood (2011) 118 (21): 4143.

https://doi.org/10.1182/blood.V118.21.4143.4143

Published: 2011

Journal Articles

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study

Peter T. Tan, MBBS, Kate Reed, BSc, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Othon L Gervasio, DDS, MS, PhD, Ivo J. Winiger, MD, Dirk Hönemann, MD, Andrew H Wei, MBBS, PhD, Andrew Spencer, MD

Blood (2011) 118 (21): 1529.

https://doi.org/10.1182/blood.V118.21.1529.1529

Published: 2011

Journal Articles

A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML

Andrew H Wei, MBBS, PhD, Sonali Sadawarte, John Catalano, MBBS, FRACP, FRCPA, Robert Hills, MA, MSc, DPhil, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, Alan Burnett, Andrew Spencer, MD

Blood (2010) 116 (21): 3299.

https://doi.org/10.1182/blood.V116.21.3299.3299

Published: 2010

Journal Articles

Clinical Activity of Azacitidine In Combination with the Oral mTOR Inhibitor Everolimus (RAD001) In Relapsed and Refractory AML: Interim Analysis of a Phase Ib/II Study

Andrew H Wei, MBBS, PhD, Sonali Sadawarte, MBBS, MD, DM, John Catalano, MBBS, FRACP, FRCPA, Anthony P. Schwarer, MD, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, Andrew Spencer, MD

Blood (2010) 116 (21): 3301.

https://doi.org/10.1182/blood.V116.21.3301.3301

Published: 2010

NARROW

Hypercalcaemia at Diagnosis Is an Independent Predictor of Poor Survival in Diffuse Large B-Cell Lymphoma

BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma

Post-Allogeneic Stem Cell Transplant Surveillance of CD34+ Sorted Peripheral Blood to Quantify Emergent DNMT3A, IDH and NPM1 clones and Correlation with Clinical Outcome

Improved Survival of Older Patients with Mantle Cell Lymphoma (MCL) with Front-Line Cytarabine-Based Immunochemotherapy

Autologous Stem Cell Transplantation (ASCT) Followed By Outpatient-Based Non-Myeloblative Allogeneic (NMA) Stem Cell Transplantation (Tandem Auto-Allo) for Biologically Adverse Multiple Myeloma (MM). a Single Centre Experience from Australia

Comparison of Cyclophosphamide/Total Body Irradiation (Cy/TBI) and Etoposide/Total Body Irradiation (Etop/TBI) Conditioned Allogeneic Stem Cell Transplant (alloHSCT) for Adult Acute Lymphoblastic Leukaemia (ALL), Data from an Australian Tertiary Care Centre

The Effect of Granulocyte-Colony-Stimulating Factor (G-CSF) on T Cell Polarization in Vitro : A Direct Comparison Between Nivestim® and Neupogen®

Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma Is Feasible, Efficacious and Associated With Low Transplant-Related Morbidity and Mortality

Incidence and Kinetics Of Full Donor Chimerism and The Impact Of Minimal Residual Disease Status Following Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma

Azacitidine in Combination with the mTOR Inhibitor Everolimus in Relapsed and Refractory AML

Initial Remission Duration Is the Most Important Predictor of Outcome Following FLAG-Amsacrine Salvage of AML in First Relapse,

A Phase 1b Dose Escalation Safety Analysis of Lenalidomide and Azacitidine Maintenance Therapy for Poor Risk AML,

A Retrospective Analysis of 344 Fludarabine Melphalan RIC Allogeneic Stem Cell Transplants for Myeloid and Lymphoid Malignancies In Australia and New Zealand 1998–2008,

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study

A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML

Clinical Activity of Azacitidine In Combination with the Oral mTOR Inhibitor Everolimus (RAD001) In Relapsed and Refractory AML: Interim Analysis of a Phase Ib/II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only